Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine to Present at 16th Annual Needham Healthcare Conference

GlobeNewswire March 28, 2017

Lipocine to Present at 27th Annual Oppenheimer Conference

GlobeNewswire March 14, 2017

Lipocine Announces Financial and Operational Results for the Full Year of 2016

GlobeNewswire March 6, 2017

Lipocine to Present at 29th Annual ROTH Conference

GlobeNewswire March 6, 2017

Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer

GlobeNewswire February 15, 2017

Research Reports Coverage on Healthcare Stocks -- Pacira Pharma, Supernus Pharma, Lipocine, and IntelliPharmaCeutics

PR Newswire January 12, 2017

Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

GlobeNewswire January 9, 2017

Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate

GlobeNewswire January 5, 2017

Lipocine to Initiate Dosing Validation Study for LPCN 1021, Oral Testosterone Replacement Product Candidate

GlobeNewswire December 5, 2016

Research Reports Initiation on Healthcare Stocks -- CVS Health, Express Scripts, UnitedHealth, and Lipocine

PR Newswire November 9, 2016

Lipocine Announces Financial and Operational Results for the Third Quarter of 2016

GlobeNewswire November 8, 2016

Lipocine Announces Issuance of US Patent 9,480,690

GlobeNewswire November 7, 2016

Lipocine Gets A Boost After News From The FDA

Benzinga.com  October 17, 2016

18 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  October 17, 2016

Lipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application

GlobeNewswire October 17, 2016

Lipocine's Positive Patent Lawsuit News Not Enough To Lift The Stock

Benzinga.com  October 13, 2016

Clarus Therapeutics Provides Update on Patent Infringement Lawsuit Against Lipocine’s Oral Product for Testosterone Replacement Therapy

GlobeNewswire October 13, 2016

14 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  October 11, 2016

Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ruby Tuesday Shares Fall Following Q1 Results

Benzinga.com  October 7, 2016

Lipocine Wins Dismissal of Patent Infringement Lawsuit Related to LPCN 1021

GlobeNewswire October 7, 2016